BioSpace News Archive

Business

Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium

Mustang Bio, Inc. today announced that City of Hope Phase 1 clinical trial data on MB-105, a prostate stem cell antigen (“PSCA”) chimeric antigen receptor (“CAR”) T-cell therapy administered systemically to patients with PSCA-positive metastatic castration-resistant prostate cancer.

February 15, 2022

·

6 min read

Theratechnologies Strengthens Global Commercial Capabilities by Launching Internal Field Force

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced the strengthening of its global commercial capabilities by launching an internal sales force.

February 15, 2022

·

6 min read

Drug Development

Last Patient Completes Treatment in Stealth BioTherapeutics’ Phase 2 Geographic Atrophy Clinical Trial

Stealth BioTherapeutics Corp announced today that the final patient in its 176-subject, ReCLAIM-2 phase 2 clinical trial for extra-foveal geographic atrophy associated with dry age-related macular degeneration (AMD) has completed treatment.

February 15, 2022

·

7 min read

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders

JCR Pharmaceuticals’ Research Presentations at WORLD Symposium ™ 2022 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders.

February 15, 2022

·

14 min read

Business

ValenzaBio and Novelty Nobility Announce Exclusive License Agreement for Potential Best-in-Class Anti-c-KIT Monoclonal Antibody

ValenzaBio, Inc. today announced an exclusive worldwide license agreement for the development and commercialization of VB517, a potentially best-in-class anti-c-KIT mAb for mast cell-driven autoimmune diseases.

February 15, 2022

·

3 min read

Bio NC

Propella Therapeutics Presents Non-Clinical Data on PRL-02 at 2022 ASCO Genitourinary (GU) Cancers Symposium

Propella Therapeutics, Inc. (“Propella”), a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, today announced that nonclinical data for its lead product candidate, PRL-02, will be featured at the 2022 ASCO Genitourinary (GU) Cancers Symposium.

February 15, 2022

·

6 min read

Deals

Twist Bioscience Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Twist Bioscience Corporation today announced the closing of its upsized underwritten public offering of 5,227,272 shares of its common stock at a public offering price of $55.00 per share.

February 15, 2022

·

4 min read

Policy

Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 8th Consecutive Year

Certara, Inc., a global leader in biosimulation, announced that 90 percent of new drug approvals by the U.S. Food and Drug Administration’s Center for Drug Evaluation and Review were received by Certara’s customers in 2021, excluding diagnostic agents.

February 15, 2022

·

2 min read

Business

Coherus Names Paul Reider Chief Commercial Officer

Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) today announced Paul Reider has been named Chief Commercial Officer.

February 15, 2022

·

4 min read

Business

On Demand Pharmaceuticals Commissions State-of-the-Art, cGMP Medicine Manufacturing Facility

On Demand Pharmaceuticals, Inc. announced the opening of its current Good Manufacturing Process compliant manufacturing facility dedicated to manufacturing all aspects of the medicine supply chain, from fine chemicals to final drug product.

February 15, 2022

·

4 min read